GlassScriptPhysician profile
Mallory Wilson Rice
NPI 1447816285
$4,020.56
in general payments reported to CMS, 2019-2025
27 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,121 · 2022: $651 · 2023: $653 · 2024: $482 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,344.65 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $475.90 | 2021-2025 | |
| Novo Nordisk INC | $338.32 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $326.99 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $192.80 | 2023-2025 | Rexulti |
| Amgen INC. | $167.53 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $138.12 | 2021-2025 | |
| Lilly USA, LLC | $120.57 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $120.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $111.27 | 2022 | |
| Corium, LLC | $91.39 | 2023-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.25 | 2022-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $80.26 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $75.87 | 2022-2025 | Quviviq, Quviviq |
| Inspire Medical Systems, INC. | $66.48 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $52.46 | 2023 | |
| Phathom Pharmaceuticals, INC. | $46.35 | 2024-2025 | Voquezna |
| Radius Health, INC. | $39.15 | 2024-2025 | Tymlos |
| Nestle Healthcare Nutrition INC. | $23.32 | 2023 | |
| Daiichi Sankyo INC. | $19.12 | 2024 | Injectafer |
| Corcept Therapeutics | $17.54 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $16.51 | 2022 | |
| Astellas Pharma US INC | $16.50 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $14.78 | 2021 | |
| Currax Pharmaceuticals LLC | $14.76 | 2021 | |
| Eisai INC. | $14.39 | 2021 | |
| Akebia Therapeutics INC | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.